Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro

European Respiratory Journal

Volumn 14, Issue 2, 1999, Pages 363-369

  Dowling, R B ^a   Johnson, M ^b   Cole, P J ^a   Wilson, R ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cilia; Epithelium; Fluticasone propionate; Organ culture; Pseudomonas aeruginosa; Salmeterol

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CYCLIC AMP; FLUTICASONE PROPIONATE; SALMETEROL;

ARTICLE; BACTERIUM ADHERENCE; CILIATED EPITHELIUM; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT MUCOSA;

ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; BACTERIAL ADHESION; BRONCHODILATOR AGENTS; CULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MUCOCILIARY CLEARANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY MUCOSA; RESPIRATORY TRACT INFECTIONS;

EID: 0032824964     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.1999.14b21.x     Document Type: Article

References (44)

1. Pitt TL. Biology of Pseudomonas aeruginosa in relation to pulmonary infection in cystic fibrosis. J R Soc Med 1986; 79 (Suppl. 12): 13-18.
2. Cole P. Bronchiectasis. In: Brewis RAL, Gibson GJ, Geddes DM, eds. Respiratory Medicine. London, Bailliere Tindall, 1995; pp. 726-759.
3. Wilson R, Dowling RB. Pseudomonas aeruginosa and other related species. Thorax 1998; 53; L213-L219.
4. Fagon JY, Chastre J. Severe exacerbations of COPD patients: role of pulmonary infections. Semin Respir Infect 1996; 11: 109-118.
5. Hoiby N. Microbiology of lung infections in cystic fibrosis patients. Acta Paediatr Scand Suppl 1982; 301: 33-54.
6. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10: 1754-1760.
7. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981; 2: 1137-1139.
8. Rayner CFJ, Tillotson G, Cole PJ, Wilson R. Efficacy and safety of long term ciprofloxacin in the management of severe bronchiectasis. J Antimicrob Chemother 1994; 34: 149-156.
9. Auerbach HS. The use of steroids in cystic fibrosis. Antibiot Chemother 1989; 42: 254-256.
10. Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for anti-inflammatory therapy in cystic fibrosis. Am Rev Respir Dis 1990; 141: 186-192.
11. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant human Dnase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87: 9188-9192.
12. Schaad UB, Lang AB, Wedgewood J, et al. Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis. Lancet 1991; 338: 1236-1237.
13. Baltimore RS, Christie CD, Smith GJ. Immunohistopathological localization of Pseudomonas aeruginosa in lungs from patients with cystic fibrosis. Implications for the pathogenesis of progressive lung deterioration. Am Rev Respir Dis 1989; 140: 1650-1661.
14. Tsang KWT, Rutman A, Tanaka E, et al. Interaction of Pseudomonas aeruginosa with human respiratory mucosa in vitro. Eur Respir J 1994; 7: 1746-1753.
15. Dowling RB, Rayner CFJ, Rutman A, et al. Effect of salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Am J Respir Crit Care Med 1997a; 155: 327-336.
16. Read R, Roberts P, Munro N, et al. Effect of Pseudomonas aeruginosa rhamnolipids on mucociliary transport and ciliary beating. J Appl Physiol 1992; 72: 2271-2277.
17. Kanthakumar K, Taylor G, Tsang KWT, et al. Mechanisms of action of Pseudomonas aeruginosa pyocyanin on human ciliary beat in vitro. Infect Immun 1993; 61: 2848-2853.
18. Tsukamato T, Nigam SK. Tight junction proteins form large complexes and associate with the cytoskeleton in an ATP depletion model for reversible junction assembly. J Biol Chem 1997; 272: 16133-16139.
19. Dowling RB, Johnson M, Cole PJ, Wilson R. The effect of rolipram, a type IV phosphodiesterase inhibitor, on Pseudomonas aeruginosa infection of respiratory mucosa. J Pharmacol Exp Ther 1997; 282: 1565-1571.
20. Azghani AO, Conelly JC, Peterson BT, Gray LD, Collins ML, Johnson AR. Effects of Pseudomonas aeruginosa elastase on alveolar epithelial permeability in guinea pigs. Infect Immun 1990; 58: 433-438.
21. Amitani R, Wilson R, Rutman A, et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. Am J Respir Cell Mol Biol 1991; 4: 26-32.
22. Dowling RB, Newton R, Robichaud A, Cole PJ, Barnes PJ, Wilson R. Effect of inhibition of nitric oxide synthase on Pseudomonas aeruginosa infection of respiratory mucosa in vitro. Am J Respir Cell Mol Biol 1999; 19: 950-958.
23. Berger M. Inflammation in the lung in cystic fibrosis: a vicious cycle that does more harm than good? Clin Rev Allergy 1991; 9: 119-142.
24. Phillipps GH. Structure activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990; 84: 10-23.
25. Esmailpour N, Hogger P, Rabe KF, Heitman U, Nakashima M, Rohdewald P. Distribution of inhlaed fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997; 10: 1496-1499.
26. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59: 597-602.
27. Ksang KWT, Ho PL, Lam WK, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med 1998; 158: 723-727.
28. Devalia JL, Sapsford RJ, Rusznak C, Toumbis MJ, Davies RJ. The effects of salmeterol and salbutamol on ciliary beat frequency of cultured human bronchial epithelial cells in vitro. Pulmon Pharmacol 1992; 5: 257-263.
29. Nials AT, Sumner MJ, Johnson M, Coleman RA. Investigations into factors determining the duration of action of the β;2-adrenoceptor agonist, salmeterol. Br J Pharmacol 1993; 108: 507-515.
30. Kanthakumar K, Cundell DR, Johnson M, et al. Effect of salmeterol on human nasal epithelial cell ciliary beating: inhibition of the ciliotoxin pyocyanin. Br J Pharmacol 1994; 112: 493-498.
31. Wilson R, Pitt T, Taylor G, et al. Pyocyanin and 1-hydroxyphenazine produced by Pseudomonas aeruginosa inhibit the beating of human respiratory cilia in vitro. J Clin Invest 1987; 79: 221-229.
32. Jackson AD, Cole PJ, Wilson R. Comparison of Haemophilus influenzae type B interaction with respiratory mucosa organ cultures incorporating an airinterface. Am J Respir Crit Care Med 1996; 64: 2353-2355.
33. Ramphal R, Pyle M. Adherence of mucoid and nonmucoid P. aeruginosa to acid-injured tracheal epithelium. Infect Immun 1983; 41: 345-351.
34. Plotkowski MC, Chevialard M, Pierrot M, et al. Differential adhesion of P. aeruginosa to human respiratory epithelial cells in primary culture. J Clin Invest 1991; 87: 2018-2028.
35. Riva CM, Morganroth L, Ljungman AG, et al. Iloprost inhibits neutrophil-induced lung injury and neutrophil adherence to endothelial monolayers. Am J Respir Cell Mol Biol 1990; 3: 301-309.
36. Nasseri-Sina P, Fawthrop DJ, Wilson J, Boobis AR, Davies DS. Cytoprotection by iloprost against paracetamol-induced toxicity in hamster isolated hepatocytes. Br J Pharmacol 1992; 105: 417-423.
37. Sekut L, Champion BR, Page K, Menius JA, Connolly KM. Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin Exp Immunol 1995; 99: 461-466.
38. Kwon OJ, Au BT, Collins PD, et al. Inhibition of interleukin-8 expression by dexamethasone in human cultured epithelial cells. Immunology 1994; 81: 389-394.
39. Flower RJ, Rothwell NJ. Lipocortin-1: cellular mechanisms and clinical relevance. Trends Pharmacol Sci 1994; 15: 71-76.
40. Castellino F, Heuser J, Marchetti S, Bruno B, Luini A. Glucocorticoid stabilization of actin filaments: a possible mechanism for inhibition of corticotropin release. Proc Natl Acad Sci USA 1992; 89: 3775-3779.
41. Mak JCW, Nishikawa M, Barnes PJ. Glucocorticosteroids increase β2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 12: L41-L46.
42. Kobilka BK, Frielle T, Dohiman HG, et al. Delineation of the intronless nature of the genes for the human and hamster β2-adrenergic receptor and their putative promoter regions. J Biol Chem 1987; 262: 7321-7327.
43. 1 and β2-adrenoceptors. Eur J Pharmacol 1986; 130: 137-139.
44. Tuomanen El, Hendley JO. Adherence of Bordetella pertussis to human respiratory epithelial cells. J Infect Dis 1983; 148: 125-130.